Article

BRAF mutation predicts sensitivity to MEK inhibition. Nature

Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA.
Nature (Impact Factor: 42.35). 02/2006; 439(7074):358-62. DOI: 10.1038/nature04304
Source: PubMed

ABSTRACT The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumours, often through gain-of-function mutations of RAS and RAF family members. Using small-molecule inhibitors of MEK and an integrated genetic and pharmacologic analysis, we find that mutation of BRAF is associated with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harbouring a RAS mutation. This MEK dependency was observed in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest. Pharmacological MEK inhibition completely abrogated tumour growth in BRAF mutant xenografts, whereas RAS mutant tumours were only partially inhibited. These data suggest an exquisite dependency on MEK activity in BRAF mutant tumours, and offer a rational therapeutic strategy for this genetically defined tumour subtype.

Download full-text

Full-text

Available from: Neal Rosen, Apr 22, 2014
0 Followers
 · 
211 Views
  • Source
    • "Tumor cell lines were from our collection or from ATCC. GI 50 were analyzed as described (Solit et al., 2006): cells were plated at a density of 1,000–2,000 cells/well and treated with the drugs for 48 hr, Alamar Blue (Invitrogen) was added, and the colorimetric change was measured at 570 and 600 nm. GI 50 was estimated by nonlinear regression using GraphPad5 Prism Software. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nearly 50% of human malignancies exhibit unregulated RAS-ERK signaling; inhibiting it is a valid strategy for antineoplastic intervention. Upon activation, ERK dimerize, which is essential for ERK extranuclear, but not for nuclear, signaling. Here, we describe a small molecule inhibitor for ERK dimerization that, without affecting ERK phosphorylation, forestalls tumorigenesis driven by RAS-ERK pathway oncogenes. This compound is unaffected by resistance mechanisms that hamper classical RAS-ERK pathway inhibitors. Thus, ERK dimerization inhibitors provide the proof of principle for two understudied concepts in cancer therapy: (1) the blockade of sub-localization-specific sub-signals, rather than total signals, as a means of impeding oncogenic RAS-ERK signaling and (2) targeting regulatory protein-protein interactions, rather than catalytic activities, as an approach for producing effective antitumor agents.
    Cancer Cell 08/2015; 28(2):170. · 23.89 Impact Factor
  • Source
    • "Tumor cell lines were from our collection or from ATCC. GI 50 were analyzed as described (Solit et al., 2006): cells were plated at a density of 1,000–2,000 cells/well and treated with the drugs for 48 hr, Alamar Blue (Invitrogen) was added, and the colorimetric change was measured at 570 and 600 nm. GI 50 was estimated by nonlinear regression using GraphPad5 Prism Software. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Graphical Abstract Highlights d DEL-22379 inhibits ERK dimerization without affecting its phosphorylation. d DEL-22379 blocks proliferation of tumor cells harboring RAS-ERK pathway oncogenes.
    Cancer Cell 08/2015; DOI:10.1016/j.ccell.2015.07.001 · 23.89 Impact Factor
  • Source
    • "BRAF mutated cells have been shown to possess enhanced sensitivity to MEK inhibition [69]. MEK inhibitors are believed to function by inducing apoptosis through suppression of Mcl-1, a member of the anti-apoptotic B-cell CLL/lymphoma 2 (Bcl-2) family [70]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Melanoma is the least common form of skin cancer, but it is responsible for the majority of skin cancer deaths. Traditional therapeutics and immunomodulatory agents have not shown much efficacy against metastatic melanoma. Agents that target the RAS/RAF/MEK/ERK (MAPK) signaling pathway-the BRAF inhibitors vemurafenib and dabrafenib, and the MEK1/2 inhibitor trametinib-have increased survival in patients with metastatic melanoma. Further, the combination of dabrafenib and trametinib has been shown to be superior to single agent therapy for the treatment of metastatic melanoma. However, resistance to these agents develops rapidly. Studies of additional agents and combinations targeting the MAPK, PI3K/AKT/mTOR (PI3K), c-kit, and other signaling pathways are currently underway. Furthermore, studies of phytochemicals have yielded promising results against proliferation, survival, invasion, and metastasis by targeting signaling pathways with established roles in melanomagenesis. The relatively low toxicities of phytochemicals make their adjuvant use an attractive treatment option. The need for improved efficacy of current melanoma treatments calls for further investigation of each of these strategies. In this review, we will discuss synthetic small molecule inhibitors, combined therapies and current progress in the development of phytochemical therapies. Copyright © 2015. Published by Elsevier Ireland Ltd.
    Cancer Letters 01/2015; 359(1). DOI:10.1016/j.canlet.2015.01.016 · 5.62 Impact Factor
Show more